CXCL10 levels in diagnosis and improved hemodynamics in patients with chronic thromboembolic pulmonary hypertension undergoing balloon pulmonary angioplasty

Figures

• 

  Figure 1. Plasma chemokine (C‐X‐C motif) ligand 10 (CXCL10) levels of healthy controls and chronic thromboembolic pulmonary hypertension (CTEPH) patients undergoing balloon pulmonary angioplasty (BPA). (a)Plasma CXCL10 levels of CTEPH patients at baseline, at the last BPA session, and of healthy controls. (2) CTEPH patients' plasma CXCL10 levels at baseline and at their last BPA sessions in matched pairs. (3) Changes of plasma CXCL10 levels during BPA treatment.

• 

  Figure 2. Subgroup analysis of chemokine (C‐X‐C motif) ligand 10 (CXCL10) levels in chronic thromboembolic pulmonary hypertension (CTEPH) patients and balloon pulmonary angioplasty (BPA) sessions. (a) Comparison of CXCL10 levels between patients who received pulmonary arterial hypertension (PAH)‐targeted therapy and those who did not, at baseline and at the last BPA session (23 patients with PAH‐targeted therapy vs. 15 patients without PAH‐targeted therapy). (b) Comparison of preoperative CXCL10 levels between BPA sessions with complications and those without complications (89 sessions without complications vs. 11 sessions with complications).

• 

  Figure 3. Correlations of preoperative plasma chemokine (C‐X‐C motif) ligand 10 (CXCL10) levels with (a) mean right atrial pressure (RAP), (b) systolic pulmonary artery pressure (PAP), (c) diastolic PAP, (d) mean PAP, (e) pulmonary vascular resistance (PVR), and (f) N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) undergoing balloon pulmonary angioplasty (n = 100 sessions).

• 

  Figure 4. Diagnostic value of chemokine (C‐X‐C motif) ligand 10 (CXCL10) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). (a) Receiver operating characteristic curve analysis of CXCL10 for diagnosis of CTEPH. (b) Forest plot of the multivariate logistic regression of CXCL10 adjusting for sex and age. (c) A nomogram for differentiating CTEPH patients from healthy controls.

• 

  Figure 5. Preoperative chemokine (C‐X‐C motif) ligand 10 (CXCL10) and related models for prediction of balloon pulmonary angioplasty (BPA)‐related complications. (a) Receiver‐operating characteristic curve (ROC) analysis of Model 1 and Model 2 for prediction of complications in BPA. (b) Forest plot of the multivariate logistic regression of Model 1 and Model 2. Nomograms of (c) Model 1 and (d) Model 2 for predicting complications in BPA. NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; PAP, pulmonary artery pressure; PVR, pulmonary vascular resistance.